Nivolumab Plus Ipilimumab Prolongs PFS in MSI-H/dMMR mCRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 69
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2025 AND VI 26 AND IP 3
Results: 19
1
2
First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 67
- By:
- Publication type:
- Article
3
Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 66
- By:
- Publication type:
- Article
4
NIPS Boosts Overall Survival in Gastric Cancer With Peritoneal Metastasis.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 64
- By:
- Publication type:
- Article
5
Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 62
- By:
- Publication type:
- Article
6
Diving Into the JAMA Publication.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 59
- Publication type:
- Article
7
EXPERTS EXAMINE THE DEVELOPMENT OF SECONDARY PRIMARY CANCERS AFTER CAR T-CELL THERAPY.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 56
- By:
- Publication type:
- Article
8
UNDERSTANDING the Patient Experience in Blood Cancer Treatment.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 54
- Publication type:
- Article
9
Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 50
- By:
- Publication type:
- Article
10
CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 48
- By:
- Publication type:
- Article
11
Investigators Look to Add Duvelisib to Treatment Arsenal of Rare T-Cell Lymphoma Subtype.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 42
- By:
- Publication type:
- Article
12
Immunogenomic Properties Predict Exceptional Responses to Immune Checkpoint Inhibition in RCC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 39
- By:
- Publication type:
- Article
13
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 32
- By:
- Publication type:
- Article
14
Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 24
- By:
- Publication type:
- Article
15
Encorafenib Combination Approval Paves the Way Forward in BRAF V600E-Mutated CRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 18
- By:
- Publication type:
- Article
16
Durvalumab Shifts Decades-Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 16
- By:
- Publication type:
- Article
17
FDA Digest.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 14
- Publication type:
- Article
18
Ethical Considerations in the Conduct of Clinical Cancer Research: ALWAYS A TIMELY TOPIC.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 12
- By:
- Publication type:
- Article
19
The First Quarter of 2025 Features an Abundance of Exciting Research.
- Published in:
- OncologyLive, 2025, v. 26, n. 3, p. 7
- By:
- Publication type:
- Article